{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.59","value":"-0.6"},{"groupId":"OG001","spread":"2.46","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.65","value":"0.0"},{"groupId":"OG001","spread":"3.15","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.56","value":"-0.1"},{"groupId":"OG001","spread":"2.98","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.11","value":"-0.2"},{"groupId":"OG001","spread":"2.88","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.57","value":"-0.4"},{"groupId":"OG001","spread":"3.45","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.71","value":"-0.2"},{"groupId":"OG001","spread":"3.22","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"title":"Cycle 13, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.92","value":"-0.2"},{"groupId":"OG001","spread":"3.08","value":"-0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"Cycle 15, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.54","value":"-0.3"},{"groupId":"OG001","spread":"2.06","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.59","value":"-0.1"},{"groupId":"OG001","spread":"1.95","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Cycle 19, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.39","value":"-0.1"},{"groupId":"OG001","spread":"2.89","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 21, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.20","value":"-0.0"},{"groupId":"OG001","spread":"2.61","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 23, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.65","value":"0.4"},{"groupId":"OG001","spread":"3.00","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 25, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.53","value":"0.2"},{"groupId":"OG001","spread":"1.92","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Cycle 27, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.83","value":"-0.2"},{"groupId":"OG001","spread":"2.15","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.11","value":"0.0"},{"groupId":"OG001","spread":"1.33","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 31, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.88","value":"-0.2"},{"groupId":"OG001","spread":"1.40","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 33, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.77","value":"0.1"},{"groupId":"OG001","spread":"1.33","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Cycle 35, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.78","value":"0.4"},{"groupId":"OG001","spread":"2.65","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 37, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.70","value":"0.1"},{"groupId":"OG001","spread":"1.15","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 39, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.00","value":"0.1"},{"groupId":"OG001","spread":"1.15","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 41, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.07","value":"-0.1"},{"groupId":"OG001","spread":"0.71","value":"0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 43, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.64","value":"-0.7"},{"groupId":"OG001","spread":"0.00","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 45, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.77","value":"-2.8"},{"groupId":"OG001","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 47, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.28","value":"0.3"},{"groupId":"OG001","spread":"3.55","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"Final visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its \"worst in last 24 hours,\" \"least in last 24 hours,\" \"average,\" and \"now\" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"OG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"OG001","title":"Placebo + Bortezomib and Dexamethasone"}],"paramType":"MEAN","populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization; participants who have both baseline and post-baseline values are included in the analysis at each visit","reportingStatus":"POSTED","timeFrame":"Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment","title":"Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain","type":"SECONDARY","unitOfMeasure":"units on a scale"}